AxoGen, Inc.
AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosā¦ read more
Healthcare
Medical Devices
39 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$32.64
Price-0.61%
-$0.20
1Y
Price
Market Cap
$1.501b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+21.1%
EBITDA Margin+1.2%
Net Profit Margin+2.3%
Free Cash Flow MarginRevenue
$214.709m
+14.6%
1y CAGR+15.7%
3y CAGR+14.0%
5y CAGREarnings
-$2.097m
+79.0%
1y CAGR+52.7%
3y CAGR+37.7%
5y CAGREPS
-$0.05
+78.3%
1y CAGR+53.1%
3y CAGR+38.3%
5y CAGRBook Value
$120.805m
$216.400m
Assets$95.595m
Liabilities$67.914m
DebtDebt to Assets
31.4%
3.2x
Debt to EBITDAFree Cash Flow
$2.853m
+25836.4%
1y CAGR+8660.4%
3y CAGR+6498.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company